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Abstract
Background: Coronavirus disease 2019 (COVID-19) pandemic has raised concerns
about the susceptibility amongst different groups of the population. Pregnant women
are one such group. This study was conducted to investigate the effect of COVID-19
on pregnancy and maternal/neonatal outcomes.
Case presentation: This case series was conducted on 16 pregnant women with
COVID-19 from March 21 to May 11, 2020. Clinical characteristics, pregnancy
complications, medication used, maternal/neonatal outcomes, and fatality rate were
investigated through this study. The mean age of the patients was 30.06 yrs. Patients
from all three trimesters were included (1 in first, 5 in second, and 10 in the third
trimesters). The most common clinical symptoms were shortness of breath (n = 10), dry
cough (n = 10), myalgia (n = 8), and chills (n = 7). Also, three cases had papulosquamous
skin lesions with fissuring. The most common laboratory results were leukocytosis (n
= 8), increased liver enzymes (n = 6), elevated CRP (n = 5), and thrombocytopenia (n =
4). There was one case of maternal mortality, five of premature labor pain (PLP), two
of preeclampsia, and two of placenta accreta. Twelve pregnancies were terminated
(nine cesarean sections, three vaginal deliveries). Among neonates, we had 6 cases of
preterm labor. All neonates had negative PCR results.
Conclusion: Clinical manifestations and paraclinical results were similar to non-
pregnant patients. There was no evidence of vertical transmission. PLP and premature
rupture of membranes (PROM) were the most common complications in the second
and third trimesters of pregnant COVID-19 women, which can lead to rupture of the
uterus. Termination and delivery should be planned individually.
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1. Introduction
Coronavirus disease 2019 (COVID-19) has
caused a mass infection in 213 countries/territories
thus far (1). On March 11, 2020, COVID-19 was
declared as a pandemic by the World Health
Organization (WHO) (2). The high number of
infected cases has raised concerns about
susceptible groups in the general population.
Pregnant women constitute a concerning
group.
Pregnancy causes physiologic changes in
women’s immune systems, which can have adverse
effects on maternal and neonatal outcomes during
viral infections (3). Previous studies shown a more
severe course of the disease in pregnant women
with influenza virus infection (4). Also, previous
coronavirus epidemics, such as the severe acute
respiratory syndrome (SARS) and the Middle-East
respiratory syndrome (MERS), have shown to
cause serious complications during pregnancy (5,
6).
As shown previously, SARS increased the
rate of spontaneous miscarriage in the first
trimester, preterm delivery, intrauterine growth
restriction (IUGR), and maternal death in pregnant
women. A case-controlled trial on SARS patients
reported a more severe clinical course and
poorer outcomes in pregnant women compared
to non-pregnant patients (7-10). MERS has caused
an increase in maternal death rate, premature
delivery, and perinatal morbidity in pregnant
women (6, 11).
Some studies have investigated the effect
of COVID-19 during pregnancy. However,
most of the studies were small case series
from China investigating women during the
third trimester of pregnancy (12-16). Therefore,
more information is needed regarding the
effect of COVID-19 during different trimesters
of pregnancy to guide treatment and prevent
complications in pregnant women with COVID-
19.
In this study, we conducted a multicenter
retrospective case series on pregnant women
with COVID-19 to investigate the effect of the
disease on pregnancy and maternal/neonatal
outcomes. To the best of our knowledge,
this is the largest case series from Iran to
date.
2. Case presentation
2.1. Study design and patient
collection
In this case series, 16 pregnant women infected
with COVID-19 who were referred to three
university hospitals affiliated with Shiraz University
of Medical Sciences from March 21 to May 11,
2020 were included. These pregnant women
were identified by the discharge diagnosis.
Pregnant women with confirmed for diagnosis
of COVID-19 were included in this study. The
confirmation was done if at least two of the
following three criteria were met: (I) Positive
reverse-transcriptase-polymerase-chain-reaction
(RT-PCR) results for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) (II)
Abnormal imaging findings (chest CT scan or
chest X-ray [CXR]) in favor of COVID-19; and (III)
Clinical symptoms of viral pneumonia in favor of
COVID-19.
2.2. Data collection
Data collection was done using paper
medical records of the included patients
and self-reported histories. Data, including
patients’ self-reported past medical
histories, self-reported past medication
histories, clinical characteristics, laboratory
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results, imaging findings, treatment course,
and maternal/neonatal outcomes were
collected.
2.3. Ethical considerations
This study was approved by the ethics
committee of Shiraz University of Medical Sciences
(IR.SUMS.REC.1399.589) and in accordance
with the Declaration of Helsinki. In addition,
all patients gave a written informed consent
for using their medical information in research
projects.
2.4. Results
The mean age of the patients was 30.06 years
and ranged from 19 to 37 years old. One case
was in the first, five in the second, and ten in the
third trimester. Eight cases were hospitalized from
the beginning with the impression of COVID-19,
and the other cases were admitted due to other
reasons such as preterm labor (n = 5), receiving
chemotherapy for ovarian dysgerminoma in 20
wks of pregnancy (n = 1), and preeclampsia in
the third trimester of pregnancy (n = 2). COVID-19
was detected in other patients during the hospital
course. The duration of hospital admission was
between 5 and 15 days for most of the patients.
However, patient number 11 was hospitalized
for 35 days, which is described in detail later.
Four patients were admitted to the intensive
care unit (ICU; patient numbers 6, 8, 10, and
11).
2.5. Clinical characteristics
The most common clinical symptoms include
shortness of breath (n = 10), dry cough (n
= 10), myalgia (n = 8), and chills (n = 7). In
addition, high-grade fever was found in 2 cases
(temperature 41°C), 10 cases presented with
low-grade fever (temperature < 38°C), and 5
cases were afebrile. Three cases had COVID-19-
related papulosquamous lesions with fissuring
that appeared before other manifestations of
the disease (Figure 1). Moreover, decreased
blood oxygen saturation (O2 saturation <
93%) was seen in four cases, and headache
appeared in two patients. Two patients had
a body mass index (BMI) of over 30 in this
period of time (cases number 5 and 12). In
terms of underlying diseases, six patients had
hypothyroidism and were under treatment of
levothyroxine with normal TSH, and one patient
(case number 5) with ovarian dysgerminoma
was under chemotherapy. Table I presents the
patients’ basic information and initial clinical
characteristics.
2.6. Paraclinical findings
CXR reports showed pleural effusion in
eight patients and ground glass appearance
in five cases; however, three cases had
normal CXR findings. High-resolution
computed tomography (HRCT) added more
information than X-ray to our findings in 11
patients. All details are provided in Table
II.
Moreover, positive results of nasopharynx
and oropharynx specimens for COVID-19 RT-
PCR were reported in 12 patients. Leukopenia
was not seen in our patients, except for case
number 5, who developed leukopenia during
the course of chemotherapy and was managed
with one dose of granulocyte colony-stimulating
factor (GCSF). However, leukocytosis (WBC
10400-20000 × 109/L) was seen in eight patients.
Elevated C-reactive protein (CRP) levels were
seen in five patients. Thrombocytopenia was
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found in four patients without any other signs
and symptoms of preeclampsia syndrome.
Also, six patients had significantly increased
liver enzymes (2-18 folds). Table II presents
the laboratory results and imaging findings
and differences between CXR and HRCT of all
patients.
2.7. Maternal and neonatal outcomes
In total, we had one case of maternal mortality
(case number 11), one of massive myocardial
infarction, and one patient with pulmonary
thromboembolism (PTE) with anticoagulant
therapy. In cases number 8 and 10, hysterectomy
was done due to placenta accreta. Among all
cases, 12 pregnancies were terminated. Nine
pregnancies were terminated with cesarean
section (two cases in the second trimester
admitted with premature labor pain (PLP) and
terminated due to medication unresponsiveness
and seven cases in the third trimester that were
terminated due to preeclampsia [n = 2, PLP n
= 2, and three cases due to term pregnancy].
Three In addition, three cases had normal vaginal
delivery (two patients due to PLP and one case
with term pregnancy). Among neonates, we had
six cases of preterm labor (case number 1 was
terminated due to PLP and HELLP syndrome at
29 wks of gestation; case number 4 had a vaginal
delivery at home after being discharged from
hospital in 26 wks of gestation due to PLP and
premature rupture of membrane (PROM); cases
number 6 and 11 was terminated due to PROM
and PLP at 31 wks of gestation). We had 2 There
were two cases of placenta accreta who were
terminated at 21 and 24 weeks of gestation due
to PLP and rupture of the uterus; both fetuses
were expired. Also, we had one case of small
for gestational age (SGA) who delivered at 36
weeks of gestation due to oxytocin challenge
test positive result, one case of IUGR and mild
preeclampsia at 37 wks of gestation, and one case
of meconium staining at 39 wks of gestation. We
had 8 Eight cases needed neonatal intensive care
unit (NICU) admission after birth, as described in
Table III. Eight neonates were breastfed according
to health protocols; none of them had PCR positive
test, illness, or death until now. Maternal and
neonatal outcomes are summarized in Table
III.
Medications such as hydroxycholoroquine,
lopinavir, and oseltamivir were used for the
management of COVID-19. Antibiotics such
as meropenem, vancomycin, ceftriaxone,
and azithromycin were also administered. All
medications used in the course of hospitalization
are listed (Table IV).
Here, we described the detailed hospital course
of four patients with interesting clinical findings
(cases number 4, 9, 10, and 11)
2.8. Case number 4
A 24-yrs-old lady, Gravida 1, at 25 weeks of
pregnancy, was admitted to hospital with chief
complaint of headache, palpitation, and shortness
of breath, and without any history of direct contact
to COVID-19-infected patient. Her symptoms at
the time of hospitalization included tachycardia
(PR = 160/min), tachypnea (RR = 40/min), O2
saturation < 93% without using oxygen, and
temperature 41°C. The patient did not have any
sign of coughing, sneezing, or rhinorrhea but
had palmoplantar papulosquamous lesions with
fissuring with nailbed involvement. Her BMI was
about 24 and did not have any past medical
histories. Primary lab results showed lymphopenia
(WBC 7200 × 109/L, Lymphocyte 0.4%), mildly
elevated liver enzymes (AST = 86, ALT = 56 U/L),
CRP 96 mg/L, PT 15, and PTT 40.
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There were no abnormalities in the primary
CXR, but after two days of hospitalization,
echocardiography was done for her due to
persistent tachycardia, and bilateral moderate
amount of pleural effusion was found incidentally.
Additionally, HRCT was performed, and
pleural effusion and the pleural band was
detected in her left lung lower lobe. During
the hospital course, the patient developed
decreased platelet count (66000 × 109/L,
38000, and 15000) with three episodes of
epistaxis during five days. The result of the
nasopharyngeal swab for COVID-19 RT-PCR was
negative.
Based on these findings, antibiotic therapy
and hydroxychloroquine were started for
her, and the patient was admitted to the
intensive unit care (ICU) ward. Also, lopinavir
(200 mg/twice weekly) and IVIG (400
mg/kg/day) were started due to progressive
thrombocytopenia and tachypnea. Urine
protein test and LDH levels were in the normal
range.
After five days of treatment, the platelet level
returned to normal, and the patient’s clinical
symptoms improved gradually. After 14 days
of hospital admission, she was discharged
from the hospital. However, five days after
her discharge, she developed a sudden
onset rupture of membrane and labor pain
and inevitably delivered a 900-gr baby at
home. Her baby was admitted to the NICU
ward and is currently in good condition
there.
2.9. Case number 9
A 37-year-old lady, Gravida 3 Live 2, at
37 weeks of gestation, was admitted to the
hospital with the impression of IUGR and mild
preeclampsia. She had a history of direct
contact with a COVID-19-infected patient (her
sister). At the time of hospitalization, the
patient was febrile (38°C) and had a history
of dry cough, anorexia, shortness of breath,
myalgia, and abdominal pain since four days
before the admission. Her past medical history
was hypothyroidism and gestational diabetes
mellitus (on medication) with a BMI of 28.8, and
positive nasopharyngeal swab RT-PCR COVID-19
test.
Her pregnancy was terminated through
the cesarean section route according to the
gestational age. She was observed with the
continuation of conservative management,
hydroxychloroquine, and a prophylactic dose of
anticoagulant. However, on the third postoperative
day, the patient developed tachypnea and
decreased oxygen saturation. A chest CT
scan was performed for her, and the following
findings were reported: bilateral pleural effusion
and consolidation in the base of both lungs
with a sign of clot formation in the right
interlobar artery and posterior basal segment
infiltration.
Heparin therapy was started for her with an
impression of PTE. She was discharged after 14
days, with the administration of warfarin.
2.10. Case number 10
A 34-year-old woman, Gravida 5 Abortion 3
Live 1 Dead 1 (with a history of two previous
cesarean sections), was admitted to our hospital
in a shock state at 24 weeks of pregnancy. She
did not report any direct contact with a COVID-
19 patient. On admission, she had decreased
hemoglobin level (6 g/dl), and fast abdominopelvic
sonography reported severe free fluid in her
abdomen. She was immediately transferred
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to the operation room with the impression
of placenta percreta and ruptured uterus in
disseminated intravascular coagulation (DIC)
state, and emergency hysterectomy was done.
Subsequently, pelvis packing with long gauze
was done due to massive transfusion and oozing
from the site of operation. The patient was then
transferred to the ICU ward after the operation.
Her primary lab results included WBC 10,000 ×
109/L (Neutrophil count 7,400 and Lymphocyte
count 2,000), platelet 36,000 × 109/L, AST 560,
ALT 170 U/L, PT 13, PTT 73, CRP 137 Mg/L, and
ESR 26. Her nasopharyngeal sample for COVID-
19 RT-PCR was negative; however, moderate
pleural effusion of both lungs was reported in
CXR. The abdominal pack was removed 48
hr after the operation, and the patient was
extubated. Furthermore, bilateral pneumo catheter
insertion was done, and pleural effusion was
drained.
In the follow-up, HRCT results showed a
pleural band in the lower lobe of the left
lung with bilateral pleural effusions. She had
negative results of pleural fluid culture and a
normal level of procalcitonin. During the one
week of hospital admission, the patient came
out from DIC state and was transferred to the
sub-ICU ward with good condition and normal
echocardiography findings. Broad-spectrum
antibiotics were administered during her course
of hospitalization. On day 11 of admission,
she developed cardiac arrest and posterior
inferior ST-elevation myocardial infarction with
troponin level over 2,000 ng/ml troponin. She was
referred for emergency percutaneous coronary
intervention (PCI). The result of PCI showed
mild healed dissection in the mid and distal
part of the main left coronary artery (MLCA).
Echocardiography was done and reported
25% ejection fraction. Medical treatments
were started for her. After 35 days of hospital
admission and teamwork management, she
was discharged in good condition, normal
chest CT scan, and 35% ejection fraction in
the last echocardiography report. Although her
RT-PCR results were negative, her respiratory
symptoms, cardiovascular complications, and
primary lab results were in favor of COVID-19
infection.
2.11. Case number 11
A 28-year-old lady, Gravida 5 Abortion 1
Dead 1 Live 2 (with a history of one previous
cesarean section), was referred to our hospital
with PLP and placenta accreta. The patient
had past medical histories of hypothyroidism
and minor thalassemia. On admission, she
was febrile (temperature 38°C), and her first
day of admission lab results included WBC
12,700 (Neutrophil count 6,850 and Lymphocyte
count 4,950), platelet 138,000, and creatinine
level 0.8 μmol/L. She was transferred to the
operation room due to constant contraction and
progression in vaginal examination patients.
Cesarean section was performed with the
impression of focal accreta. Six hours after
the operation, the patient developed tachycardia
(pulse rate = 140), tachypnea (respiratory rate
= 24), and she was still febrile (38°C). Vaginal
examination and abdominopelvic sonography
were normal. Hemoglobin level was 11 × 109/L,
and electrocardiogram (ECG) showed sinus
tachycardia. CXR was done and showed bilateral
ground-glass appearance and bilateral pleural
effusion.
The patient was transferred to the COVID-19
ward with the impression of COVID-19 pneumonia,
and antibiotic therapy was started for her.
She developed decreased urinary output (20
cc/hr) 24 hr later, her creatinine level increased
to 1.3 μmol/L, and she still had tachycardia.
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Echocardiography was done that showed right-
side heart failure and acute respiratory distress
syndrome (ARDS) pattern with troponin level
measuring about 2,000 ng/ml, and increasing
AST level to 127U/L. She underwent conservative
management. However, after 24 hr, she developed
decreased O2 saturation < 93% and persistent
tachycardia. PTE was ruled out for her according
to spiral chest CT scan report. Echocardiography
was performed again to find a cause for her
tachycardia and O2 saturation decrease. She
developed a cardiorespiratory arrest during the
second echocardiography and died after 2 hr of
resuscitation.





















Patient 1 25 29 PLP𝑏 Low _ + + _ _ _ _ _ _
Patient 2 39 15 COVID-19pneumonia High + + + _ + + + _ _
Patient 3 19 39 COVID-19pneumonia Low + + + + _ + _ _ _
Patient 4 24 26 COVID-19pneumonia High _ _ + _ + + _ _ +





No _ _ _ _ _ _ _ _ _
Patient 6 31 31 PLP Low + + + + _ _ _ + +
Patient 7 34 36 Preeclampsia No _ + _ _ _ _ _ _ _
Patient 8 40 21 PLP No _ _ _ _ _ _ _ _ _
Patient 9 37 37 Preeclampsia Low _ + + + _ _ _ _ _
Patient 10 34 24 PLP No _ _ _ _ _ _ _ _ _
Patient 11 28 31 PLP Low _ _ _ _ _ _ _ + +
Patient 12 32 39 COVID-19pneumonia No + _ _ + _ _ _ _ _
Patient 13 32 10 COVID-19pneumonia Low + + + + + + _ + +
Patient 14 30 37 COVID-19pneumonia Low _ + + + _ + _ + +
Patient 15 24 39 COVID-19pneumonia Low + + + + _ + + _ +
Patient 16 29 19 COVID-19pneumonia Low + + + + + _ _ _ _
𝑎High-grade fever is defined as temperature > 38°C, 𝑏PLP: Premature labor pain
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4700 349000 96 17 13 6 0.7 13 30 - +
Patient 3 Normal Normal 7000 202000 2.9 153 74 9 0.9 14 33 - +
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effussion








12700 138000 3 127 53 28 1.3 24 57 - -

























and pleural effusion 6600 183000 3 23 10 10 0.8 13 30 - +
CXR: Chest X-ray, HRCT: High-resolution computed tomography, WBC: White blood cell, PLT: Platelet, CRP: C-reactive protein, AST: Serum glutamic-oxaloacetic
transaminase, ALT: Glutamic-pyruvic transaminase, BUN: Blood urea nitrogen, Cr: Creatinine, PT: Prothrombin time, PTT: Partial thromboplastin time, U/P: Urine
protein, PCR: Polymerase chain reaction
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Patient 1 _ NVD _ _ PLP, HEELP _ Yes/ Preterm + _
Patient 2 _ _ _ _ _ _ _ _
Patient 3 _ C/S _ _ SGA,OCT + Abdominal wallhematoma No + _
Patient 4 + NVD _ _ PLP, PROM _ Yes/ Preterm _ _
Patient 5 _ _ _ _ _ _ _ _
Patient 6 + C/S _ _ PLP, PROM _ Yes/ Preterm + _
Patient 7 _ C/S _ _ Pre-eclampsia _ Yes/SGA + _





hypertension No/dead _ _
Patient 9 _ C/S PTE _ IUGR,Preeclampsia PTE Yes/IUGR + _













Yes/ Preterm _ _
Patient 12 _ C/S _ _ LP, BX _ Yes/ Thickmeconium + _
Patient 13 _ _ _ _ _ _ _ _
Patient 14 + C/S _ _ LP _ No + _
Patient 15 _ NVD _ _ LP, ROM _ No + _
Patient 16 _ _ _ _ _ _ _ _
C/S: Cesarean section, NVD: Normal vaginal delivery, PTE: Pulmonary thromboembolism, LP: Labor pain, BX: Breech presentation, ROM: Rupture
of membrane, ARDS: Acute respiratory distress syndrome, IUGR: Intra uterine growth retard, SGA: Small for gestational age
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1 gr Q8 hr
Vancomycin
1 gr Q8 hr
Ceftriaxone
1 gr Q12 hr
Azithromycin
250 mg Qd ×
5 days
Heparin Others
Patient No. 1 + 5 days + 14 days + 14 days + Mgso 4
Patient No. 2 + 12days + 14 days + + +
Patient No. 3 + 14 days + 200 mgq12 hr + + 14 days + GSCF
Patient No. 4 + 14 days + 200 mgq12 hr + + 14 days + + + IVIG
Patient No. 5 + 14 days +
Patient No. 6 + 14 days + 14 days + + +
Patient No. 7 + 5 days + 14 days + + + Mgso 4
Patient No. 8 + 5 days + + Mgso 4
Patient No. 9 + 14 days +
Patient No. 10 + 5 days + 200 mgq12 hr +
Patient No. 11 _ + 14 days + +
Patient No. 12 _ +
Patient No. 13 + 5 days + 14 days +
Patient No. 14 + 5 days + 14 days +
Patient No. 15 + 5 days + 14 days +
Patient No. 16 + 5 days + 14 days +
Figure 1. Cutaneous papulosquamous lesions with fissuring and erosions.
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3. Discussion
The rapid spread of coronavirus disease needs
timely intervention to protect the lives of mothers
and fetuses infected with the virus. Despite the
low risk of death with COVID-19 infection in the
general population, we are concerned about the
progression of the disease, the lower respiratory
tract’s involvement, and the need for invasive
ventilation in this group of patients (17, 18). However,
there are no reports of high-risk COVID-19 amongst
pregnant women, and there is a lack of evidence
that pregnancy increases the chance of getting the
disease (19, 20).
The clinical appearances of SARS and MERS
virus infection in pregnancy are different and
include a wide range of clinical manifestations. The
common clinical symptoms of COVID-19 patients
include fever and dry cough. In our referral hospital,
the most common symptoms of patients were low-
grade fever, shortness of breath, and dry cough,
while other symptoms like headache, abdominal
pain, and diarrhea were less common (21, 22).
Among the severe forms of the disease needing
ICU care (cases number 4, 7, 8, 10, 11, 14),
fever was detected in only 50% of patients upon
hospitalization. Our findings are similar to Guan
and colleagues (23). Therefore, it can be concluded
that having a fever is not a specific criterion for
determining the severity of the disease. Despite
previous studies in which all patients were in the
third trimester of pregnancy, we presented 1 case
in the first, 5 in the second, and 10 in the third
trimesters of pregnancy (12-16). For termination of
pregnancies, the decision was made according to
maternal-fetal conditions and gestational age (24).
On comparison of the findings of CXR and HRCT,
it should be noted that in 12/16 cases, the chest
CT scan added more information to CXR. CXR
appeared normal in four cases (cases number 3,
4, 10, 12); however, in cases number 4 and 10, the
presentation of disease and HRCT findings were
different from CXR. The sensitivity of HRCT in the
detection of COVID-19 pneumonia was about 98%
higher than PCR (71%) (25).
HRCT was introduced as a noninvasive and
conventional modality with high accuracy and
sensitivity in detection of COVID-19 pneumonia in
the early stages of the disease. Similar to Pan and
colleagues (26), we could follow the progression
of the disease or evaluate the response to medical
therapy by using multiple chest CT scans. A chest
CT scan can show the healing process even
before the negative result of the RT-PCR test (26,
27). Although it cannot differentiate COVID-19
pneumonia from other viral types of pneumonia,
we must consider COVID-19 diagnosis and isolate
patients during this active pandemic period.
Therefore, in suspicious patients with negative
RT-PCR results, we considered a combination of
exposure history, clinical symptom, and chest CT
findings for detecting COVID-19 patients.
The most common finding in laboratory results
was leukocytosis. The CRP level also had a direct
contribution to the severity of the disease.
In critical patients with elevated liver enzymes
and serum creatinine levels, a prerenal pattern
was seen. Vascular emboli are associated
with increased D-dimer and troponin levels,
especially in the acute phase of the disease.
Thrombocytopenia was seen as a severity sign of
COVID-19 pneumonia in 40-45% of patients (28).
We also had thrombocytopenia in critical cases
that were related to multiple episodes of epistaxis.
Fang and colleagues. reported 71% sensitivity
for the PCR test in the detection of the disease
(25). Among the 16 patients admitted to our ward
with suspicion of COVID-19 pneumonia, 11 had a
positive nasooropharynx swab PCR test. However,
among the six severe cases of the disease, only
two had a positive nasopharyngeal PCR swab tests.
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According to recent studies, a positive PCR swab
test is one of the most important criteria in the
detection, isolation, and treatment of patients with
COVID-19 (29). However, sometimes conversely,
more positive PCR tests are seen in subacute cases
rather than in critical cases with lower respiratory
tract infection due to: immature development of
nuclear acid detection technology; variation in the
detection rate of the virus in different manufacture
kits; lower viral load in the upper respiratory tract;
improper clinical sampling and sampling during
different periods of disease development and
relatively long processing time. Therefore, the RT-
PCR test is not highly sensitive for diagnosing lower
respiratory tract infection with COVID-19 (25, 27).
We presented three critical cases with massive
inferior-posterior wall myocardial infarction,
PTE, acute right-sided heart failure, and death
against prophylactic doses of heparin that
was administered for them. COVID-19 can
induce multiple organ injury with the following
hypothetical mechanism: cytokine storm
phenomena; hypoxic injury; coronary arteries
spasm; and direct endothelial vascular injury that
induces microthromboses (30). In case number
10, inferior-posterior wall STEMI occurred in the
presence of nonobstructive disease on coronary
angiography and led to myocardial injury with 25%
cardiac ejection fraction in echocardiography. The
troponin level was over 2,000 and 2,300 ug/ml D-
Dimer level at 11 days of ICU ward hospitalization,
respectively. Patients did not have any risk factors
for heart disease. Also, abnormal coagulation
parameter was reported in severe cases of
COVID-19 pneumonia. It could lead to vascular
thromboembolism events due to the dysregulation
of urokinase pathways (31). In these cases, the PT
and PTT time was prolonged.
The majority of women in our hospital affected
by COVID-19 were treated with broad-spectrum
antibiotics and hydroxychloroquine.
Hydroxychloroquine was used as a
cost-effective, anti-inflammatory, and
immunomodulatory drug to adequately penetrate
the lung tissue. Because of these characteristics,
it was considered as a treatment of COVID-
19 pneumonia (32, 33). It is an experimental
drug without any strong evidence of its
efficacy for COVID-19 pneumonia. We used
hydroxychloroquine in 12 cases (500 mg twice
daily for 5-10 days). We also used lopinavir as an
antiviral drug in two cases with severe form of
COVID-19 who recovered (cases number 3, 4).
Several case-control studies of Covid 19 have
examined the results of 41 pregnant women in
the third trimester of pregnancy (12-16). The most
common symptoms were fever and dry cough with
increased CRP levels and liver enzymes. No severe
illness was seen in any of them, and the infants’
weight in these mothers did not differ from the
normal population. Complications of pregnancy
observed in them were similar to our observation,
that is, PLP, PROM, and fetal distress. Viral PCR test
did not detect virus particles in the amniotic fluid,
umbilical blood.
Furthermore, throat swabs of neonates, breast
milk, and maternal vaginal swabs did not detect
viral particles. According to our findings, PLP
and PROM were the most common complications
that threatened COVID-19 mothers during the
second and third trimesters. It can lead to
catastrophic results, especially in mothers with a
history of previous cesarean section (rupture of the
uterus).
In SARS and MERS epidemic, vertical
transmission in the perinatal period was not
reported. In COVID-19, one infant with a positive
PCR test just 30 hr after birth was reported as a
questionable vertical transmission case. However,
it has not yet been determinedwhether the disease
was transmitted during pregnancy or after birth.
Page 202 https://doi.org/10.18502/ijrm.v19i2.8477
International Journal of Reproductive BioMedicine COVID-19 manifestations in pregnancy
Further, no vertical transmission in pregnancy on
covid-19 was observed (12, 14). Viral PCR test of
amniotic fluid, umbilical cord blood, throat swab of
neonates, maternal vaginal swabs, and breast milk
of mothers were negative in four recent studies
(12-15). In this study, we had breastfeeding in eight
cases without any reports of COVID-19 sign and
symptoms in babies. Although there is not enough
data to determine how long the infected mother
should separate from the baby, so we advised
mothers to follow the health tips techniques during
breastfeeding until complete recovery.
Based on the available findings to reduce
maternal and neonatal complications during the
COVID-19 pandemic, the following suggestions
can be given in the diagnosis and treatment of
pregnant women: (i) Early diagnosis of COVID-19
can be made using the combination of exposure
history, clinical symptoms, chest CT findings, and
RT-PCR test for detecting Covid19 women. (ii)
Also, it is important to pay attention to certain
lab results in the severe form of the disease,
including thrombocytopenia, elevated D-dimer,
liver enzyme (AST, ALT) levels, and their course
of progression of the disease. (iii) Team-based
approach and multispecialty consultations are
needed in the management of these patients. (iv)
Empiric antibiotic therapy should be administered
to prevent the second bacterial infection risk in
these patients. (v) Fetal and uterine contraction
monitoring should be done in these patients.
(vi) Individual delivery plan should be given
to pregnant COVID-19 patients based on their
condition.
4. Conclusion
Clinical manifestations and paraclinical results
of pregnant women with COVID-19 were similar
to non-pregnant COVID-19 patients. Fever was
detected in only 50% of the patients upon
hospitalization; therefore, it is not a specific
feature for the diagnosis of the COVID-19 during
pregnancy. Cutaneous lesions can be the first
symptoms in COVID-19 pregnant patients. There
is no evidence of vertical transmission in our
cases. PLP and PROM were the most common
complications in the second and third trimesters
of pregnant COVID-19 women, which can lead
to rupture of uterus in those with a history
of previous cesarean section. Termination and
delivery plans should be given individually based
on each patients’ condition.
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